Analyzing Progression Free Survival: A Meta-analysis of 28 Trials to Explore the Impact of Censoring Rules.
*Jonathan Denne, Eli Lilly Renee Iacona, Eli Lilly Andrew Stone, Eli Lilly
A PhRMA working group on Progression Free Survival was established in 2008 to consider issues related to the use of this endpoint for drug approval, and improve study design and analysis. One important topic addressed was that concerning how to handle missing data, and other issues in follow-up, such as patients who start other anti-cancer therapy prior to progression, or who miss scans. Regulatory guidance differs in how to handle these situations. In order to explore the impact of different rules for handling these situations, a meta-analysis was conducted using the results of defined analyses on 28 trials submitted by the participating representatives. The results of this meta-analysis, comparing several censoring rules with an ITT approach, will be presented.
April 30 - May 22, 2013
Invited Abstract Submission Open
June 4, 2013
Online Registration Opens
August 9 - August 23, 2013
Invited Abstract Editing
August 23, 2013
Short Course materials due from Instructors
August 26, 2013
September 9, 2013
Cancellation Deadline and Registration Closes @ 11:59 pm EDT
September 16 - September 18, 2013
Marriott Wardman Park, Washington, DC